EXEL

Exelixis, Inc. (EXEL) - Q1 2008 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 28, 2008. Exelixis, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule drugs for cancer and other serious diseases. The company has no approved products and relies on collaboration agreements with major pharmaceutical partners (including Bristol-Myers Squibb, Genentech, and GlaxoSmithKline) for funding and commercialization. The company operates under a 52-53 week fiscal year.

Key Financial Metrics

Note: The company reported a net loss of $41.3 million, driven primarily by increased R&D expenses. Cash and cash equivalents decreased by approximately $13.6 million during the quarter.

Material Changes vs. Prior Period

• Revenue Composition: While total revenue remained relatively flat ($27.9M vs $28.1M), the mix shifted significantly. Milestone revenue increased by $7.8 million (from $2.9M to $10.7M) due to payments from Bristol-Myers Squibb ($20M milestone for XL139) and Genentech ($3M milestone for XL518). Conversely, research and development funding revenue decreased by $4.4 million, largely due to the divestiture of the Artemis Pharmaceuticals subsidiary and the conclusion of the Daiichi-Sankyo agreement.
• Operating Expenses: Research and Development (R&D) expenses increased by 31% to $66.0 million (from $50.2 million). This increase was driven by the initiation of Phase 3 activities for XL184 and XL647, and Phase 1/2 activities for multiple other compounds. General and Administrative (G&A) expenses decreased by 22% to $8.7 million, primarily due to the re-allocation of corporate costs to R&D.
• Cash Flow: Operating cash flow swung from a positive $44.8 million in Q1 2007 to a negative $39.2 million in Q1 2008. The 2007 positive flow was heavily influenced by a $60M upfront payment from Bristol-Myers Squibb and a $15M milestone from Genentech, which were recognized as deferred revenue and subsequently amortized or utilized in 2008.

Guidance, Outlook, and Risks

• Clinical Developments:
  • XL647: The company decided to delay the planned Phase 3 trial. Instead, it will initiate a new Phase 2 trial in 2008 as a first-line agent for non-small cell lung cancer. Phase 3 is now expected around mid-2009.
  • XL518: Genentech exercised its option to develop and commercialize this compound, triggering a $3.0 million milestone. Genentech will lead development after the Maximum Tolerated Dose (MTD) is determined.
  • XL139: Bristol-Myers Squibb exercised its option, triggering a $20.0 million milestone. Exelixis opted to co-develop and co-commercialize in the U.S., sharing costs and profits.
  • XL335: Wyeth Pharmaceuticals discontinued development of this compound in April 2008.
• Liquidity and Capital Resources: As of March 31, 2008, the company held $252.2 million in cash, cash equivalents, and marketable securities. Management anticipates these resources, combined with expected collaboration funding, will sustain operations for at least 12 months. However, substantial additional funding will be required for future clinical trials.
• Financial Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with its loan agreement with GlaxoSmithKline. As of March 31, 2008, the company was in compliance ($178.7M working capital; $246.9M cash/investments).
• Key Risks:
  • SEI Repurchase Option: Exelixis has an option to repurchase three compounds (XL647, XL784, XL999) from Symphony Evolution, Inc. (SEI). The repurchase price is $80M plus 25% annual compound interest. If not exercised by June 2009, Exelixis loses rights to these assets. XL999 was discontinued, and XL784 was declined by GSK, increasing the pressure to find partners or repurchase.
  • Dependence on Partners: Revenue is entirely dependent on collaboration milestones and funding. Delays in partner decisions or clinical failures could materially impact financial results.
  • Regulatory Uncertainty: No products are approved; all candidates face lengthy and uncertain regulatory processes.

Investor Verification Checklist

• SEI Repurchase Timeline: Verify the status of discussions regarding the repurchase of XL647, XL784, and XL999 from Symphony Evolution, Inc., given the June 2009 deadline and the compounding cost.
• XL647 Clinical Strategy: Confirm the timeline and design of the new Phase 2 trial for XL647 in non-small cell lung cancer and the implications of delaying the Phase 3 trial.
• GlaxoSmithKline Loan Covenants: Monitor quarterly compliance with the $25M working capital and $50M cash/investment covenants, especially as R&D burn rates increase.
• Partner Milestone Triggers: Track the progress of XL518 (Genentech) and XL139 (Bristol-Myers Squibb) to assess the timing of future milestone payments (e.g., the $7M Genentech Phase 2 initiation milestone).
• Cash Burn Rate: Analyze the sustainability of the current cash position ($121.9M cash + $79.5M short-term securities) against the projected $66M quarterly R&D spend and the need for future capital raises.